In July 2025, Vertex Pharmaceuticals Incorporated conducted a study is to evaluate the pharmacokinetics, safety, tolerability ...

The NHS will offer a once-daily triple therapy for cystic fibrosis to hundreds more patients, including those with rare ...

Vertex Pharmaceuticals has solidified its leadership in the cystic fibrosis (CF) market through strategic innovation and ...

Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

It said that 95% of people with cystic fibrosis in England will now be eligible for modulator therapy. The new drug, also ...

In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and superior in reducing sweat chloride compared to ...

About a third of lung transplant patients with cystic fibrosis receive elexacaftor-tezacaftor-ivacaftor; use is higher among ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

In cystic fibrosis, thick mucus builds up in the lungs, making it difficult to breathe. This inherited disease, which is typically diagnosed by age 2, can also lead to frequent lung infections and ...

Importantly, treatment of patients with cystic fibrosis with the natural serine protease inhibitor α1-antitrypsin for 4 weeks reduced the levels of free elastase in their lungs, increased the ...

Cystic fibrosis thickens mucus throughout the body — including mucus in the cervix. Thicker mucus makes it harder for the man’s sperm to swim into the cervix and fertilize an egg.